[go: up one dir, main page]

PE20190500A1 - Moduladores del receptor nmda spiro-lactam y uso de los mismos - Google Patents

Moduladores del receptor nmda spiro-lactam y uso de los mismos

Info

Publication number
PE20190500A1
PE20190500A1 PE2019000292A PE2019000292A PE20190500A1 PE 20190500 A1 PE20190500 A1 PE 20190500A1 PE 2019000292 A PE2019000292 A PE 2019000292A PE 2019000292 A PE2019000292 A PE 2019000292A PE 20190500 A1 PE20190500 A1 PE 20190500A1
Authority
PE
Peru
Prior art keywords
nmda
lactam
spiro
same use
alkyl
Prior art date
Application number
PE2019000292A
Other languages
English (en)
Inventor
M Amin Khan
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of PE20190500A1 publication Critical patent/PE20190500A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a un compuesto que tiene la formula expuesta, o una sal farmaceuticamente aceptable y/o un estereoisomero del mismo, caracterizado porque: R1 se selecciona de H, fenilo, entre otros; R2 se selecciona de forma independiente de H, alquilo-C1-C4, y haloalquilo-C1-C4; R3, R4, R6 y R7 se seleccionan de forma independiente de H, hidroxilo, etc; R5a se selecciona de H, ciano, entre otros; y R5b se selecciona de H, alquilo-C1-C4, entre otros; y a formulaciones o composiciones farmaceuticas que comprenden al compuesto de la invencion (pueden ser mezclas racemicas o estereoisomericas variadas de uno o mas de estos) junto a un excipiente farmaceuticamente aceptable (segun la via de administracion). Tambien se refiere a metodos de preparacion y de tratamiento (para esto se pueden emplear tambien terapias de combinacion con uno o mas de otros agentes activos). La presente invencion es util para el tratamiento de afecciones tales como depresion y trastornos relacionados mediante la modulacion de la actividad del receptor N-metil-d-aspartato (NMDA).
PE2019000292A 2016-08-01 2017-08-01 Moduladores del receptor nmda spiro-lactam y uso de los mismos PE20190500A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662369465P 2016-08-01 2016-08-01
US201762523413P 2017-06-22 2017-06-22

Publications (1)

Publication Number Publication Date
PE20190500A1 true PE20190500A1 (es) 2019-04-10

Family

ID=59593189

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000292A PE20190500A1 (es) 2016-08-01 2017-08-01 Moduladores del receptor nmda spiro-lactam y uso de los mismos

Country Status (17)

Country Link
US (2) US10961189B2 (es)
EP (1) EP3490974B1 (es)
JP (1) JP7036792B2 (es)
KR (1) KR102503590B1 (es)
CN (1) CN109906218B (es)
AU (1) AU2017306136B2 (es)
BR (1) BR112019001921A2 (es)
CA (1) CA3031534C (es)
CL (1) CL2019000246A1 (es)
CO (1) CO2019000941A2 (es)
ES (1) ES2972533T3 (es)
IL (1) IL264488A (es)
MX (1) MX385336B (es)
PE (1) PE20190500A1 (es)
PH (1) PH12019500207A1 (es)
SG (1) SG11201900558RA (es)
WO (1) WO2018026763A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
CN105229011B (zh) 2013-01-29 2018-02-06 阿普廷伊克斯股份有限公司 螺‑内酰胺nmda受体调节剂及其用途
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
CN114685277A (zh) * 2020-12-31 2022-07-01 苏州瑞博生物技术股份有限公司 化合物及羟基丙酸盐类化合物的纯化方法
CN113956183B (zh) * 2021-10-28 2023-06-20 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法
WO2024054919A1 (en) * 2022-09-08 2024-03-14 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3360503A (en) * 1963-04-09 1967-12-26 Du Pont Process for preparing poly(alpha, alpha-disubstituted beta-lactams)
DE2048080C3 (de) * 1970-09-30 1979-11-29 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen
EP0180398A1 (en) * 1984-10-26 1986-05-07 The Regents Of The University Of California Synthesis of beta-lactam
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5350769A (en) 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
CA2058223A1 (en) * 1991-12-20 1993-06-21 Bing-Yan Zhu Process for preparing beta-lactams
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
EP0914333B1 (en) 1996-06-07 2004-11-24 AstraZeneca AB Peptide derivatives
US5959075A (en) 1996-08-02 1999-09-28 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
WO1999024584A1 (en) 1997-11-12 1999-05-20 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
WO2000027790A1 (en) 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001036685A2 (en) 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
AU782678B2 (en) 2000-02-01 2005-08-18 Agy Therapeutics, Inc. Interaction of NMDA receptor with protein tyrosine phosphatase
JP2001261679A (ja) 2000-03-21 2001-09-26 Mitsui Chemicals Inc ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
AU2001268467A1 (en) 2000-06-14 2001-12-24 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
CA2413974A1 (en) 2000-06-22 2001-12-27 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
WO2002047535A2 (en) 2000-12-14 2002-06-20 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
US20030065138A1 (en) 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
WO2002072609A2 (en) 2001-03-12 2002-09-19 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
BR0312414A (pt) 2002-07-05 2005-05-10 Targacept Inc Compostos de n-aril diazaespirociclico e métodos para a preparação e uso dos mesmos
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2004232939A1 (en) 2003-04-17 2004-11-04 Merck Sharp & Dohme Corp. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
EP1776362A1 (en) 2003-07-18 2007-04-25 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
EP1660634A4 (en) 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20070275990A1 (en) 2003-11-13 2007-11-29 Ono Pharmaceutical Co., Ltd. Heterocyclic Spiro Compound
ATE499373T1 (de) 2004-01-08 2011-03-15 Hoffmann La Roche Diazaspiropiperidinderivate
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
CN101090902B (zh) 2004-10-13 2013-05-29 默沙东公司 Cgrp受体拮抗剂
ES2392454T3 (es) 2005-03-24 2012-12-10 Emory University Régimen de dosificación para el tratamiento de una lesión cerebral traumática con progesterona
CA2620361C (en) 2005-08-26 2014-10-14 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
EP2061792A2 (en) 2006-09-15 2009-05-27 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
EP2142537A2 (en) 2007-03-20 2010-01-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
CA2716375C (en) 2008-02-20 2018-05-29 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
MX2010013946A (es) 2008-06-24 2011-02-15 Intervet Int Bv Composiciones transdermicas farmaceuticas y metodo para tratar la inflamacion en ganado.
RU2011102523A (ru) 2008-06-27 2012-08-10 Ньюросерч А/С (DK) Новые производные тетраметил-замещенного пиперидина и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов
CN102112442B (zh) 2008-08-07 2014-12-10 弗·哈夫曼-拉罗切有限公司 制备大环的方法
GB0814991D0 (en) * 2008-08-15 2008-09-24 Glaxo Group Ltd Compounds
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
US8329904B2 (en) 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
WO2011003064A2 (en) 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
DK2985032T3 (en) 2009-10-05 2019-04-15 Univ Northwestern GLYX TO USE TO TREAT ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR HUNTINGTON'S DISEASE
US8871208B2 (en) 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
EP2516439B1 (en) 2009-12-21 2014-01-22 Novartis AG Diaza-spiro[5.5]undecanes as orexin receptor antagonists
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
SG183265A1 (en) 2010-02-11 2012-09-27 Univ Northwestern Secondary structure stabilized nmda receptor modulators and uses thereof
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
CN102267995A (zh) 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
TW201245116A (en) 2010-08-12 2012-11-16 Tetraphase Pharmaceuticals Inc Tetracycline analogs
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
AP3339A (en) 2011-03-14 2015-07-31 Boehringer Ingelheim Int Benzodioxane inhibitors of leukotriene production
KR101309156B1 (ko) * 2011-03-24 2013-09-17 삼성에스디아이 주식회사 리튬 이차 전지용 전해액 및 이를 포함하는 리튬 이차 전지
MX357761B (es) 2011-04-27 2018-07-23 Univ Northwestern Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
WO2013001448A1 (en) 2011-06-27 2013-01-03 Koninklijke Philips Electronics N.V. Ultrasound transducer assembly and method of manufacturing the same
WO2013010275A1 (en) 2011-07-18 2013-01-24 The Governors Of The University Of Alberta Catalysts and processes for the hydrogenation of amides
ES2564671T3 (es) 2011-07-27 2016-03-28 Astrazeneca Ab Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
WO2013091507A1 (zh) 2011-12-20 2013-06-27 Qian Wei 杂环胺基烷氧基取代的喹唑啉衍生物及其用途
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
CN102936216B (zh) 2012-12-05 2015-03-04 南京药石药物研发有限公司 7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法
PE20151438A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
CN105229011B (zh) 2013-01-29 2018-02-06 阿普廷伊克斯股份有限公司 螺‑内酰胺nmda受体调节剂及其用途
MX375286B (es) 2013-01-29 2025-03-06 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
ES2618421T3 (es) 2013-01-29 2017-06-21 Aptinyx Inc. Moduladores espiro-lactama del receptor NMDA y usos de los mismos
CN103171641B (zh) 2013-03-19 2015-07-15 浙江大学 具备轮动功能的弹跳机器人
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
GB2528480A (en) 2014-07-23 2016-01-27 Givaudan Sa Improvements in or relating to organic compounds
GB201416346D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN112218866A (zh) 2018-01-31 2021-01-12 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US20210308101A1 (en) 2019-11-11 2021-10-07 Aptinyx Inc. Methods of treating fibromyalgia
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2021112987A1 (en) 2019-12-04 2021-06-10 Aptinyx Inc. Methods of treating cognitive impairment associated with neurodegenerative disease

Also Published As

Publication number Publication date
CL2019000246A1 (es) 2019-06-21
MX385336B (es) 2025-03-18
CA3031534C (en) 2023-10-17
CO2019000941A2 (es) 2019-02-08
PH12019500207A1 (en) 2019-06-17
EP3490974C0 (en) 2023-12-06
MX2019001318A (es) 2019-07-01
CN109906218A (zh) 2019-06-18
AU2017306136B2 (en) 2021-10-21
US20190161442A1 (en) 2019-05-30
WO2018026763A1 (en) 2018-02-08
ES2972533T3 (es) 2024-06-13
BR112019001921A2 (pt) 2019-05-14
IL264488A (en) 2019-03-31
KR102503590B1 (ko) 2023-02-24
JP2019528259A (ja) 2019-10-10
JP7036792B2 (ja) 2022-03-15
SG11201900558RA (en) 2019-02-27
EP3490974A1 (en) 2019-06-05
CA3031534A1 (en) 2018-02-08
EP3490974B1 (en) 2023-12-06
KR20190033593A (ko) 2019-03-29
US11512051B2 (en) 2022-11-29
US20220002242A1 (en) 2022-01-06
CN109906218B (zh) 2023-01-17
AU2017306136A1 (en) 2019-01-31
US10961189B2 (en) 2021-03-30

Similar Documents

Publication Publication Date Title
PE20190500A1 (es) Moduladores del receptor nmda spiro-lactam y uso de los mismos
PE20190501A1 (es) Moduladores nmda espiro-lactam y metodos de uso de los mismos
PE20190504A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190503A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190502A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
PE20230376A1 (es) Compuestos moduladores de la diacilglicerol quinasa
MX2023003989A (es) Compuestos, composiciones y metodos.
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MX2017007489A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos.
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
MX375978B (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2.
PE20151436A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PE20151438A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
UY35612A (es) Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio
EA201171488A1 (ru) Lxr модуляторы
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
AR085549A1 (es) DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA
AR107927A1 (es) Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento